Advertisement
Clement will update attendees on key company milestones and on theprogress of the company's lead product, the Pathway PV(TM) System, which isdesigned to remove atherosclerotic plaque caused by peripheral arterialdisease. Clinical data on the system from a pivotal European multicentertrial was presented at last month's Transcatheter Cardiovascular TherapeuticsConference in Washington, D.C., by its co-principal investigator, Dr. ThomasZeller of the Heart Center in Bad Krozingen, Germany.
Advertisement
About Pathway Medical Technologies, Inc.
Pathway Medical Technologies, Inc., was founded to design, develop andmanufacture medical devices for the treatment of arterial disease. Thecompany's initial focus is treating peripheral arterial disease (PAD) morequickly, safely and effectively than existing technologies. An estimated 14million people are afflicted by PAD in the U.S., and that number is projectedto grow to over 20 million during the next 10 years. The company's PathwayPV(TM) Atherectomy System allows for a minimally invasive procedure designedto restore circulation in the peripheral arteries by removing both hard andsoft diseased tissue. For further information, visit the company's Web site atwww.pathwaymedical.com.
SOURCE Pathway Medical Technologies, Inc.
